BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

European Commission Approves First-in-Class Obicetrapib for LDL-C Reduction

- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability...

September 25, 2026 | News

Singapore Approves Wegovy as First Treatment for MASH with Liver Fibrosis

ESSENCE trial data showed 63% of participants receiving semaglutide achieved steatohepatitis resolution without worsening of liver fibrosis, compared with ...

September 23, 2026 | News

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

WuXi XDC Achieves GMP Release for Singapore Bioconjugate Manufacturing Site

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on t...

September 23, 2026 | News

NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...

September 23, 2026 | News

Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins

Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...

September 23, 2026 | News

Accro Bio Doses First Patient in Phase IIb Trial of RIPK2 Inhibitor AC-101 for Ulcerative Colitis

Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, an...

September 22, 2026 | News

Specialised Therapeutics, Incyte Expand Partnership to Bring Ruxolitinib Cream to Australia

Specialised Therapeutics announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: IN...

September 22, 2026 | News

Daiichi Sankyo, AstraZeneca’s Enhertu Wins EU Panel Backing for Early Breast Cancer

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vers...

September 21, 2026 | News

Nona Biosciences Develops AI Language Model for Fully Human Heavy-Chain-Only Antibodies

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, annou...

September 18, 2026 | News

Japan Approves Lundbeck’s Eptinezumab for Migraine Prevention in Adults

Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment ap...

September 18, 2026 | News

Altruist Biologics Supports LongBio Pharma’s LP-003 to NMPA BLA Acceptance in China

Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from c...

September 17, 2026 | News

Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome

Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...

September 15, 2026 | News

Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072

Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...

September 11, 2026 | News

Stay Connected